USPTO Patents Application 10551504

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/005152

A. CLASSIFICATION OF SUBJECT MATTER

Int. CI 7 C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02,
A61P43/00, A61K39/395

According to Internationa! Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. CI 7 C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02,
A61P43/0O, A61K39/395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) ■
MEDLINE, BIOSIS/WPI (DIALOG) , Swis3Prot/PIR/GeneSeq, Genbank/EMBL/DDBJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*

Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

Hudson P.J. et al., High avidity scFv multimers;
diabodies and triabodies, J. Immunol .Methods,
1999, Vol.231, pages 177 to 189

Kortt A. A. et al., Dimeric and trimeric anti
bodies: high avidity scFvs for cancer target
ing, Biomol.Eng., 2001, Vol.18, pages 95 to
108

Xiong D. et al., Efficient inhibition of human
B-cell lymphoma xenografts with an anti-CD20 x
anti-CD3 bispecific diabody, Cancer Lett., 2002,
Vol.177, pages 29 to 39

1-14

1-14

1-14

f*"| Further documents are listed in the continuation of Box C. I I See patent family annex.

"A"

T

"O"
"P"

Special categories of cited documents:

document defining the general state of the art which is not considered
to be of particular relevance

earlier application or patent but published on or after the international '
filing date

document which may throw doubts on priority claim(s) or which is
cited to establish the publication date of another citation or other
special reason (as specified)

document referring to an oral disclosure, use, exhibition or other means
document published prior to the international filing date but later than
the priority date claimed

T later document published after the international filing date or priority
date and not in conflict with the application but cited to understand
the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone

"V document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
05 July, 2004 (05.07.04)

Date of mailing of the international search report
20 July, 2004 (20.07.04)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.
Form PCT/ISA/210 (second sheet) (January 2004)

Telephone No.

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/005152

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*

Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

E,X

MATSUOKA S. et al., A novel type of cell death
of lymphocytes induced by a monoclonal antibody
without participation of complement, J. Exp. Med.,
1995, Vol.181, pages 2007 to 2015

Fayen J. et al., Negative signaling by anti-
HLA class I antibodies is dependent upon two
triggering events, Int . Immunol . , 1998, Vol.10,
pages 1347 to 1358

Woodle E.S. et al.. Anti-human class I MHC
antibodies induce apoptosis by a pathway that
is distinct from the Fas antigen-mediated path
way, J. Immunol., 1997, Vol.158, pages 2156 to
2164

Tahtis k. et al., Biodistribution properties
of (111) indium-labeled C-functionalized
trans-cyclohexyl diethylenetriaminepentaacetic
acid humanized 3S193 diabody and F(ab') (2),
constructs in a breast carcinoma xenograft
model, Clin. Cancer Res., 2001, Vol.7, pages
1061 to 1072

Rossi E.A. et al., Development of new multi
valent-bispecific agents for pretargeting
tumor localization and therapy, Clin. Cancer
Res., 2003, Vol.9, pages 3886S to 3896S

WO 04/033499 Al (Chugai Pharmaceutical Co.,
Ltd. ) ,

22 April, 2004 (22.04.04),
Full text
(Family: none)

1-14

1-14

1-14

1-14

1-14

1-14

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

i

i